Mihaela Munteanu
Overview
Explore the profile of Mihaela Munteanu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Necchi A, van der Heijden M, Trukhin D, Peer A, Gurney H, Alekseev B, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1252.
PMID: 39054491
Background: Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumor effects...
2.
Cicin I, Plimack E, Gurney H, Leibowitz R, Alekseev B, Parnis F, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1256.
PMID: 39054485
Background: Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective...
3.
Tokito T, Kolesnik O, Sorensen J, Artac M, Lazaro Quintela M, Lee J, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1251.
PMID: 39054476
Background: Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and clinical outcomes. Epacadostat...
4.
Cho B, Brana I, Cirauqui B, Aksoy S, Couture F, Hong R, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1254.
PMID: 39054467
Background: Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits...
5.
Lara Jr P, Villanueva L, Ibanez C, Erman M, Lee J, Heinrich D, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1253.
PMID: 39054430
Background: Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deoxygenase 1 selective inhibitor, demonstrated...
6.
Yamamoto N, Satouchi M, Doi T, Fujiwara Y, Yanagitani N, Kawa Y, et al.
Invest New Drugs
. 2024 Mar;
42(3):261-271.
PMID: 38530565
Background: Pembrolizumab plus epacadostat (indoleamine 2,3-dioxygenase-1 inhibitor) was well tolerated in Japanese patients with advanced solid tumors in part A of the nonrandomized, open-label, phase 1 KEYNOTE-434 study (NCT02862457). We...
7.
Starcea I, Bogos R, Scurtu G, Munteanu M, Russu R, Lupu V, et al.
Int J Gen Med
. 2022 Apr;
15:4187-4193.
PMID: 35469261
Background: Nephrotic syndrome (NS) is the term used for the association of edema and massive proteinuria. From a therapeutic point of view, it is important to distinguish between primitive and...
8.
Doi T, Fujiwara Y, Shitara K, Shimizu T, Yonemori K, Matsubara N, et al.
Invest New Drugs
. 2020 Jun;
39(1):152-162.
PMID: 32564277
Purpose: Part A of the open-label, phase I KEYNOTE-434 study evaluated the safety and tolerability of epacadostat, an indoleamine 2,3-dioxygenase-1 inhibitor, alone and in combination with pembrolizumab in Japanese patients...
9.
Starcea M, Gavrilovici C, Elsayed A, Munteanu M, Lupu V, Cojocaru E, et al.
Medicine (Baltimore)
. 2018 Jul;
97(27):e11300.
PMID: 29979398
Rationale: Though to be rare, calcific uremic arteriolophathy (CUA) is an ectopic calcification entity causing pain and disabilities in patients with chronic renal insufficiency, thus increasing the morbidity and mortality....
10.
Starcea M, Gavrilovici C, Munteanu M, Miron I
J Int Med Res
. 2018 Jan;
46(3):1172-1177.
PMID: 29310486
An uncommon side effect of cyclosporine A (CsA) use is posterior reversible encephalopathy syndrome (PRES). PRES usually develops because of disturbed capacity of posterior cerebral blood flow to autoregulate an...